In conclusion, the T-DM1PC, T-DM1, and PTC_T-DM1P regimens had the optimal balance between efficacy (pCR) and safety (SAE) compared to other neoadjuvant anti-HER2 regimens for early-stage and locally advanced HER2+ve breast cancer, while DFS was the highest for the PTC regimen. The gene discussed is ERBB2; the disease is breast cancer.